• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Inf

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2021 Dec 10;9(2):ofab626.
doi: 10.1093/ofid/ofab626. eCollection 2022 Feb.
Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection


Kei Miyakawa[SUP] 1 [/SUP], Sousuke Kubo[SUP] 1 2 [/SUP], Sundararaj Stanleyraj Jeremiah[SUP] 1 [/SUP], Hirofumi Go[SUP] 3 [/SUP], Yutaro Yamaoka[SUP] 1 4 [/SUP], Norihisa Ohtake[SUP] 5 6 [/SUP], Hideaki Kato[SUP] 7 [/SUP], Satoshi Ikeda[SUP] 8 [/SUP], Takahiro Mihara[SUP] 9 [/SUP], Ikuro Matsuba[SUP] 10 [/SUP], Naoko Sanno[SUP] 11 [/SUP], Masaaki Miyakawa[SUP] 12 13 [/SUP], Masaharu Shinkai[SUP] 14 [/SUP], Tomoyuki Miyazaki[SUP] 15 [/SUP], Takashi Ogura[SUP] 8 [/SUP], Shuichi Ito[SUP] 16 [/SUP], Takeshi Kaneko[SUP] 2 [/SUP], Kouji Yamamoto[SUP] 3 [/SUP], Atsushi Goto[SUP] 9 [/SUP], Akihide Ryo[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits varying degrees of protective immunity conferred by neutralizing antibodies (nAbs). In this study, we report the persistence of nAb responses over 12 months after infection despite their decreasing trend noticed from 6 months.
Methods: The study included sera from 497 individuals who had been infected with SARS-CoV-2 between January and August 2020. Samples were collected at 6 and 12 months after onset. The titers of immunoglobulin (Ig)G to the viral nucleocapsid protein (NP) and receptor-binding domain (RBD) of the spike protein were measured by chemiluminescence enzyme immunoassay. The nAb titer was determined using lentivirus-based pseudovirus or authentic virus.
Results: Antibody titers of NP-IgG, RBD-IgG, and nAbs were higher in severe and moderate cases than in mild cases at 12 months after onset. Although the nAb levels were likely to confer adequate protection against wild-type viral infection, the neutralization activity to recently circulating variants in some of the mild cases (~30%) was undermined, implying the susceptibility to reinfection with the variants of concerns (VOCs).
Conclusions: Coronavirus disease 2019 convalescent individuals have robust humoral immunity even at 12 months after infection albeit that the medical history and background of patients could affect the function and dynamics of antibody response to the VOCs.

Keywords: SARS-CoV-2; humoral immunity; neutralizing antibodies.
 
Back
Top Bottom